Induction therapy is the first, most intensive phase of leukemia treatment, and its single goal is to clear leukemia cells from the bone marrow fast enough to produce a complete remission. It usually takes about four to six weeks, often in hospital, and the drugs chosen depend on the exact type of leukemia. Recent advances have added targeted drugs and immune therapies to the classic chemotherapy backbone, so induction today looks quite different from induction a generation ago.
Below I walk through what happens during induction, how the regimens differ between leukemia types, what “remission” really means, and where the field is heading. For a broader overview of the disease itself, see our leukemia guide.
What Is Induction Therapy for Leukemia?
Leukemia treatment is usually delivered in phases: induction, then consolidation (also called intensification), and for some types, maintenance. Induction is the opening move. Its job is to reduce the leukemia burden from billions of cells to a level that can no longer be seen under the microscope.
To understand why this matters, it helps to know how normal blood cell development works. In leukemia, genetic changes in an early marrow cell cause it to multiply without maturing. These immature cells, called blasts, crowd out healthy red cells, white cells, and platelets. Induction destroys the blasts so that normal blood production can restart.
Induction alone rarely cures leukemia. Even when the marrow looks clear, small numbers of leukemia cells usually remain, which is why consolidation and sometimes a stem cell transplant follow.
Why Leukemia Needs Aggressive Early Treatment
Acute leukemias progress over days to weeks. Patients often arrive with fatigue, fevers, infections, and easy bruising, all signs of bone marrow failure. Without prompt treatment, these complications can become life-threatening.
Chronic leukemias behave differently. Chronic myeloid leukemia, for example, is usually controlled with daily oral tyrosine kinase inhibitors rather than intensive induction chemotherapy. When people talk about induction therapy, they are almost always talking about acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL).
Diagnosis Comes First: Tailoring Induction to the Leukemia
Choosing the right induction regimen depends on getting the diagnosis exactly right. The workup for diagnosing leukemia typically includes:
- Complete blood count and blood smear to look for blasts and low counts.
- Bone marrow aspiration and biopsy to measure the proportion of blasts.
- Flow cytometry to separate myeloid from lymphoid leukemia using cell surface markers.
- Cytogenetics and molecular testing to find changes such as the Philadelphia chromosome, FLT3 mutations, or the PML-RARA fusion.
These results guide which drugs are added to the backbone. Because the composition and function of bone marrow differ so much between healthy and leukemic states, the marrow sample is also the baseline against which remission is later judged.
Standard Induction Regimens by Leukemia Type
The table summarizes the well-established backbones. Individual protocols vary between centers and age groups.
| Leukemia type | Typical induction backbone | Common additions |
|---|---|---|
| AML (fit adults) | “7+3”: cytarabine for 7 days plus an anthracycline (such as daunorubicin) for 3 days | FLT3 inhibitor if FLT3-mutated; gemtuzumab ozogamicin for some CD33-positive cases |
| AML (older or less fit adults) | Lower-intensity therapy such as a hypomethylating agent (azacitidine) with venetoclax | Chosen to balance response against toxicity |
| Acute promyelocytic leukemia (APL) | All-trans retinoic acid (ATRA) plus arsenic trioxide | Chemotherapy added in higher-risk cases |
| ALL | Vincristine, a corticosteroid, and asparaginase, often with an anthracycline | Intrathecal chemotherapy to protect the brain and spinal fluid |
| Philadelphia-positive ALL | Steroid-based backbone with a tyrosine kinase inhibitor | Imatinib, dasatinib, or similar agents |
What Remission Means and How It Is Measured
About two to four weeks into induction, the blood counts fall to their lowest point, called the nadir. This is expected: the chemotherapy is emptying the marrow. As healthy cells recover, a repeat marrow test checks whether the leukemia has gone.
Complete remission is generally defined as fewer than 5% blasts in the marrow, recovery of neutrophils and platelets toward normal, and no leukemia outside the marrow. Increasingly, doctors also look for measurable residual disease (MRD), tiny amounts of leukemia detected by sensitive flow cytometry or molecular tests. A patient who is MRD-negative after induction generally has a better outlook than one who is MRD-positive, and MRD results help decide whether a transplant is recommended.
Side Effects and Supportive Care During Induction
Induction is demanding because it wipes out healthy blood cells along with leukemic ones. The main risks include:
- Infections, especially during the weeks of very low neutrophils. Fever during this time is treated as an emergency.
- Bleeding and anemia, managed with platelet and red cell transfusions.
- Tumor lysis syndrome, where dying leukemia cells release potassium, phosphate, and uric acid. Hydration and preventive medicines reduce this risk.
- Mouth sores, nausea, and hair loss from chemotherapy.
- Differentiation syndrome in APL treated with ATRA or arsenic, which needs prompt steroids.
In my practice, much of the work of induction is really supportive care: antimicrobial prophylaxis, transfusions, careful fluid balance, and close attention to new symptoms.
Recent Advances in Induction Therapy
The biggest shift has been from “one regimen fits all” to treatment built around the leukemia’s genetics. Targeted drugs, such as FLT3 inhibitors in AML and tyrosine kinase inhibitors in Philadelphia-positive ALL, are now added to induction for the patients who carry those changes.
Immune-based therapies are also moving earlier. Blinatumomab, an antibody that links T cells to B-cell leukemia cells, and inotuzumab ozogamicin, an antibody-drug conjugate, are established in B-cell ALL. CAR T-cell therapy, in which a patient’s own T cells are engineered to attack leukemia, is used for relapsed or refractory B-cell ALL. For older adults with AML, venetoclax-based combinations have made effective induction possible for people who could not tolerate 7+3. Research into how leukemia clones evolve and resist treatment continues to shape these choices.
Key Takeaways
- Induction therapy is the first, intensive phase of acute leukemia treatment, aimed at complete remission.
- Regimens differ by type: 7+3 for many AML patients, ATRA plus arsenic for APL, and multi-drug steroid-based regimens for ALL.
- Accurate diagnosis, including genetic testing, determines which targeted drugs are added.
- Remission is confirmed by bone marrow testing, and MRD results guide the next steps.
- Consolidation, maintenance, or transplant usually follows, because induction alone rarely cures leukemia.
Frequently Asked Questions
How long does induction therapy for leukemia take?
Most induction courses last about four to six weeks, including the time needed for blood counts to recover. Many patients with AML stay in hospital for most of this period, while some ALL and lower-intensity AML regimens can be given partly as an outpatient.
What happens if induction does not achieve remission?
This is called primary refractory disease. The team usually repeats testing and moves to a different regimen, which may include targeted drugs, immunotherapy, or a clinical trial, often with the aim of reaching a stem cell transplant.
Will I lose my hair during induction?
Hair loss is common with intensive chemotherapy such as 7+3 and anthracycline-containing ALL regimens. It is usually temporary, and hair typically begins to regrow after treatment ends.
Is induction therapy used for chronic leukemia?
Generally not in the same way. Chronic myeloid leukemia is usually treated with oral tyrosine kinase inhibitors, and chronic lymphocytic leukemia often with targeted oral drugs or antibody combinations rather than intensive induction.
